Shots:

• The P-III PACIFIC study involves assessing of Imfinzi vs PBO in patients with unresectable- Stage III- LA NSCLC whose disease had not progressed following concurrent platinum-based CRT.
• The updated post-hoc analyses demonstrated OS @4yrs. (49.6% vs 36.3%)- m-OS (47.5 vs 29.1mos); patients not progressed after 4yrs. (35% vs 19.5%) respectively- presented at ESMO
• The company also highlights the data of Imfinzi vs CT in the P-III CASPIAN study underscoring the long-term benefit in patients with ES-SCLC. The exploratory subgroup analysis demonstrated PFS ≥12mos. (17% vs 4.5%)- patients who were progression-free & had progression @1yr. (75% & 10%) chances of being alive @2yrs.respectively

­ Ref: AstraZeneca | Image: Al Jazeera